http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110917356-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2019-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110917356-B |
| titleOfInvention | Application of blocking tumor-derived ILT4 in adoptive T cell therapy |
| abstract | The invention provides application of the ILT4 blocking tumor origin in adoptive T cell treatment. According to the invention, researches show that the tumor-derived ILT4 has an induction effect on microenvironment T cell aging, the molecular and metabolic mechanisms of the tumor-derived ILT4 are studied in detail, preclinical models prove that the targeted ILT4 can reverse the immunosuppressive microenvironment of tumors, participate in targeted therapy of malignant tumors, a B6 mouse malignant melanoma adoptive T cell immunotherapy model is further constructed, the feasibility of blocking combined ACT therapy by ILT4 is studied, and an effective means is provided for overcoming ACT therapy drug resistance. |
| priorityDate | 2019-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 266.